Cytomegalovirus infection reactivation in multiple myeloma patients administered proteasome inhibitor-combination therapy: A disproportionality analysis in a spontaneous reporting database

被引：0
|
作者：
Kaur, Gursimran [1 ]
Lukose, Lipin [1 ]
Thomas, Beulah E. [2 ]
Viswam, Subeesh Kulangara [1 ]
机构：
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Manipal, India
[2] Sparse Hosp, Bengaluru, Karnataka, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1277
引用
收藏
页码：595 / 596
页数：2
相关论文
共 50 条
  • [1] Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
    Rikako Tabata
    Nobue Sato
    Nobuhiko Yamauchi
    Yong-Mei Guo
    Hirotaka Nakamura
    Akihito Nagata
    Chi Song-Gi
    Yosuke Minami
    Junichiro Yuda
    Annals of Hematology, 2022, 101 : 465 - 467
  • [2] Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
    Tabata, Rikako
    Sato, Nobue
    Yamauchi, Nobuhiko
    Guo, Yong-Mei
    Nakamura, Hirotaka
    Nagata, Akihito
    Chi, Song-Gi
    Minami, Yosuke
    Yuda, Junichiro
    ANNALS OF HEMATOLOGY, 2022, 101 (02) : 465 - 467
  • [3] Teratogenicity associated with antibiotic therapy; a disproportionality analysis in spontaneous reporting database
    Kalamveettil, Siyad
    Subeesh, Viswam
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 353 - 353
  • [4] Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Kunisada, Kodai
    Nomura-Yogo, Moe
    Oda, Yuki
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    ACTA HAEMATOLOGICA, 2024,
  • [5] Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
    Staci L. Haney
    Michelle L. Varney
    Jacob T. Williams
    Lynette M. Smith
    Geoffrey Talmon
    Sarah A. Holstein
    Experimental Hematology & Oncology, 11
  • [6] Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma
    Haney, Staci L.
    Varney, Michelle L.
    Smith, Lynette M.
    Holstein, Sarah A.
    BLOOD, 2019, 134
  • [7] Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
    Haney, Staci L.
    Varney, Michelle L.
    Williams, Jacob T.
    Smith, Lynette M.
    Talmon, Geoffrey
    Holstein, Sarah A.
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [8] Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma
    Kim, Byung-Gyu
    Choi, Sung Hee
    Huong Nguyen
    Liang, Fu-Sen
    Kim, Seong-Jin
    Letterio, John
    Huang, Alex
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Tumor lysis syndrome associated with bruton's tyrosine kinase inhibitor: A disproportionality analysis in a spontaneous reporting database
    Viswam, Subeesh Kulangara
    Zeba, Zeba
    Shettigar, Amrutha
    Kheterpal, Aarushi
    Dhas, Ashwin
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 594 - 594
  • [10] Pulmonary related adverse events associated with bruton's tyrosine kinase inhibitor: A disproportionality analysis in a spontaneous reporting database
    Viswam, Subeesh Kulangara
    Shettigar, Amrutha
    Zeba, Zeba
    Dhas, Ashwin
    Kheterpal, Aarushi
    Kaur, Gursimran
    Lukose, Lipin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 223 - 223
12345